By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – GenMark Diagnostics today reported a net loss of $5.4 million, or $.27 per share in the fourth quarter, compared to a net loss of $3.5 million, or $.30 per share, a year ago.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.
Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.
A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.
The White House says ethical discussions about genome editing of the human germline are needed.